Vera Therapeutics (VERA) Accounts Payables (2020 - 2026)

Vera Therapeutics (VERA) has 7 years of Accounts Payables data on file, last reported at $13.9 million in Q1 2026.

• Quarterly Accounts Payables rose 50.17% year-over-year to $13.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.9 million (up 50.17% YoY) and the FY2025 annual result came in at $21.9 million, up 185.69% from the prior year.
• Accounts Payables fell to $13.9 million in Q1 2026, from $21.9 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $21.9 million in Q4 2025 to a low of $4.6 million in Q3 2024.
• A 5-year average of $10.2 million and a median of $9.3 million in 2025 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2022 — Accounts Payables soared 765.78% — and 2024, when it slumped 64.88%.
• Tracing VERA's Accounts Payables over 5 years: stood at $12.0 million in 2022, then slipped by 7.28% to $11.1 million in 2023, then sank by 31.06% to $7.7 million in 2024, then jumped by 185.69% to $21.9 million in 2025, then plunged by 36.48% to $13.9 million in 2026.
• The last three Accounts Payables figures came in at $13.9 million (Q1 2026), $21.9 million (Q4 2025), and $18.0 million (Q3 2025), per Business Quant data.